Physician profile
Christopher Coughlin
NPI 1033558739
$6,283.19
in general payments reported to CMS, 2019-2025
15 companies · $1,452 in 2025
The $1,452 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $862 · 2022: $1,090 · 2023: $1,467 · 2024: $1,413 · 2025: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,331.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,253.17 | 2021-2025 | Lux-Dx Insertable Cardiac Monitor, Rhythmia Mapping System, Emblem Mri S-Icd |
| Abbott Laboratories | $1,586.48 | 2021-2025 | Aveir, Jot Dx, Gallant |
| Medtronic, INC. | $607.32 | 2021-2024 | Aurora Ev-Icd Mri Surescan, Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan |
| Novartis Pharmaceuticals Corporation | $367.66 | 2022-2025 | |
| Biotronik INC. | $322.61 | 2021-2024 | Amvia Edge |
| E.R. Squibb & Sons, L.L.C. | $251.83 | 2022-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $214.37 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $160.77 | 2021-2025 | Farxiga |
| Chiesi USA, INC. | $122.74 | 2021-2025 | Kengreal |
| Amgen INC. | $119.08 | 2021-2025 | Repatha |
| Pfizer INC. | $72.06 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.15 | 2021-2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $62.57 | 2025 | Assure Wcd |
| Edwards Lifesciences Corporation | $39.63 | 2025 | Sapien 3 Ultra Resilia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.75 | 2021-2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Coughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.